171 related articles for article (PubMed ID: 34773261)
21. Ligelizumab for chronic spontaneous urticaria.
Sabroe RA
Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
[TBL] [Abstract][Full Text] [Related]
24. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
Berger W; Gupta N; McAlary M; Fowler-Taylor A
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
[TBL] [Abstract][Full Text] [Related]
27. Ligelizumab for Chronic Spontaneous Urticaria.
Weinberger M
N Engl J Med; 2020 Feb; 382(6):579. PubMed ID: 32023385
[No Abstract] [Full Text] [Related]
28. Ligelizumab for Chronic Spontaneous Urticaria.
Cohen JM
N Engl J Med; 2020 Feb; 382(6):579. PubMed ID: 32023384
[No Abstract] [Full Text] [Related]
29. Ligelizumab for Chronic Spontaneous Urticaria. Reply.
Center DM
N Engl J Med; 2020 Feb; 382(6):580. PubMed ID: 32023387
[No Abstract] [Full Text] [Related]
30. Ligelizumab for Chronic Spontaneous Urticaria. Reply.
Maurer M; Giménez-Arnau AM; Metz M
N Engl J Med; 2020 Feb; 382(6):579-580. PubMed ID: 32023386
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM; Arm JP; Boulet LP; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ; Laviolette M; Carlsten C; Lazarinis N; Watson RM; Milot J; Swystun V; Bowen M; Hui L; Lantz AS; Meiser K; Maahs S; Lowe PJ; Skerjanec A; Drollmann A; O'Byrne PM
J Allergy Clin Immunol; 2016 Oct; 138(4):1051-1059. PubMed ID: 27185571
[TBL] [Abstract][Full Text] [Related]
32. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
33. Safety of Methotrexate in Chronic Urticaria Unresponsive to Omalizumab.
Unsel M
Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):500-504. PubMed ID: 34418904
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.
Sussman G; Hébert J; Gulliver W; Lynde C; Yang WH; Papp K; Gooderham M; Chambenoit O; Khalil S; DeTakacsy F; Vieira A; Rihakova L
J Allergy Clin Immunol Pract; 2020; 8(7):2372-2378.e5. PubMed ID: 32272284
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Ji Y; Calonder C; Kirsilä T; Burciu A; Tisu M; Joubert Y; Laurent N; Hua E; Patekar M; Drollmann A; Woessner R
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765235
[TBL] [Abstract][Full Text] [Related]
36. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria.
Ornek S; Kocaturk E
Cutan Ocul Toxicol; 2021 Dec; 40(4):305-311. PubMed ID: 34212792
[TBL] [Abstract][Full Text] [Related]
37. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
38. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
40. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.
Giménez-Arnau AM; Salman A
Drugs; 2020 Nov; 80(16):1617-1634. PubMed ID: 32857360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
